JP2013056919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013056919A5 JP2013056919A5 JP2012253103A JP2012253103A JP2013056919A5 JP 2013056919 A5 JP2013056919 A5 JP 2013056919A5 JP 2012253103 A JP2012253103 A JP 2012253103A JP 2012253103 A JP2012253103 A JP 2012253103A JP 2013056919 A5 JP2013056919 A5 JP 2013056919A5
- Authority
- JP
- Japan
- Prior art keywords
- ylcarbonyl
- diazabicyclo
- nonane
- octane
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 5-chlorofuran-2-ylcarbonyl Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- AFIZEQKQIKDZQH-UHFFFAOYSA-N (5-chlorofuran-2-yl)-(3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound O1C(Cl)=CC=C1C(=O)N1CC(C2)CNCC2C1 AFIZEQKQIKDZQH-UHFFFAOYSA-N 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims 2
- ZJOMXSOGGLLQHD-UHFFFAOYSA-N (3-bromo-1,2-oxazol-5-yl)-(3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound O1N=C(Br)C=C1C(=O)N1CC(C2)CNCC2C1 ZJOMXSOGGLLQHD-UHFFFAOYSA-N 0.000 claims 1
- MTYYINDDZCLHDE-UHFFFAOYSA-N (3-bromofuran-2-yl)-(3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound C1=COC(C(=O)N2CC3CNCC(C3)C2)=C1Br MTYYINDDZCLHDE-UHFFFAOYSA-N 0.000 claims 1
- WYTGRFGLIURWGC-UHFFFAOYSA-N (3-chlorofuran-2-yl)-(3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound C1=COC(C(=O)N2CC3CNCC(C3)C2)=C1Cl WYTGRFGLIURWGC-UHFFFAOYSA-N 0.000 claims 1
- NEWJHZNVOKNDPN-UHFFFAOYSA-N (5-bromofuran-2-yl)-(3,7-diazabicyclo[3.3.1]nonan-3-yl)methanone Chemical compound O1C(Br)=CC=C1C(=O)N1CC(C2)CNCC2C1 NEWJHZNVOKNDPN-UHFFFAOYSA-N 0.000 claims 1
- GRGNROOZPLBVQQ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2,4-oxadiazol-3-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1N=CON=1 GRGNROOZPLBVQQ-UHFFFAOYSA-N 0.000 claims 1
- QIGLSJSYGRNPDH-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2,4-oxadiazol-5-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=NC=NO1 QIGLSJSYGRNPDH-UHFFFAOYSA-N 0.000 claims 1
- MDHUVGZAFNJECO-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2,4-thiadiazol-3-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1N=CSN=1 MDHUVGZAFNJECO-UHFFFAOYSA-N 0.000 claims 1
- IRTZKSSONMSQSU-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2,4-thiadiazol-5-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=NC=NS1 IRTZKSSONMSQSU-UHFFFAOYSA-N 0.000 claims 1
- TXWHMYDLPZCWIE-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2-oxazol-3-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1C=CON=1 TXWHMYDLPZCWIE-UHFFFAOYSA-N 0.000 claims 1
- TUNZBRSJHDFFIW-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2-oxazol-4-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1C=NOC=1 TUNZBRSJHDFFIW-UHFFFAOYSA-N 0.000 claims 1
- DFVICVZMQQSUPU-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2-oxazol-5-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CC=NO1 DFVICVZMQQSUPU-UHFFFAOYSA-N 0.000 claims 1
- VZMAGOWVMVDXLQ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2-thiazol-3-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1C=CSN=1 VZMAGOWVMVDXLQ-UHFFFAOYSA-N 0.000 claims 1
- GCXUNLAEQCEZLQ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2-thiazol-4-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1C=NSC=1 GCXUNLAEQCEZLQ-UHFFFAOYSA-N 0.000 claims 1
- WTQVLMLAAMFODI-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,2-thiazol-5-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CC=NS1 WTQVLMLAAMFODI-UHFFFAOYSA-N 0.000 claims 1
- HWSQOKGBQJLNMR-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3,4-oxadiazol-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=NN=CO1 HWSQOKGBQJLNMR-UHFFFAOYSA-N 0.000 claims 1
- AVHFVARUCSGYLN-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3,4-thiadiazol-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=NN=CS1 AVHFVARUCSGYLN-UHFFFAOYSA-N 0.000 claims 1
- CWYMBKHGVCNXNE-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3-oxazol-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=NC=CO1 CWYMBKHGVCNXNE-UHFFFAOYSA-N 0.000 claims 1
- GJUCFPVXKILPNP-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3-oxazol-4-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=COC=N1 GJUCFPVXKILPNP-UHFFFAOYSA-N 0.000 claims 1
- CRHHYTWGPWXCHF-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3-oxazol-5-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CN=CO1 CRHHYTWGPWXCHF-UHFFFAOYSA-N 0.000 claims 1
- YWMBDQMOCVVNIT-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3-thiazol-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=NC=CS1 YWMBDQMOCVVNIT-UHFFFAOYSA-N 0.000 claims 1
- NRAKAUREFGQJMW-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3-thiazol-4-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CSC=N1 NRAKAUREFGQJMW-UHFFFAOYSA-N 0.000 claims 1
- IMQZMVGZKPQKQQ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(1,3-thiazol-5-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CN=CS1 IMQZMVGZKPQKQQ-UHFFFAOYSA-N 0.000 claims 1
- UXOBDWKUWQKDRV-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(furan-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CC=CO1 UXOBDWKUWQKDRV-UHFFFAOYSA-N 0.000 claims 1
- KIUXROKMRBBOBZ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(furan-3-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C=1C=COC=1 KIUXROKMRBBOBZ-UHFFFAOYSA-N 0.000 claims 1
- HZQBHNQELXWIPY-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl(pyridin-4-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C1=CC=NC=C1 HZQBHNQELXWIPY-UHFFFAOYSA-N 0.000 claims 1
- VTBIZWJLVIDQFW-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(3-bromo-1,2-oxazol-5-yl)methanone Chemical compound O1N=C(Br)C=C1C(=O)N1CC2CNCC2C1 VTBIZWJLVIDQFW-UHFFFAOYSA-N 0.000 claims 1
- CRCWSASAEVRBQR-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(3-bromofuran-2-yl)methanone Chemical compound C1=COC(C(=O)N2CC3CNCC3C2)=C1Br CRCWSASAEVRBQR-UHFFFAOYSA-N 0.000 claims 1
- XXKYVKOMLITFKH-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(3-chlorofuran-2-yl)methanone Chemical compound C1=COC(C(=O)N2CC3CNCC3C2)=C1Cl XXKYVKOMLITFKH-UHFFFAOYSA-N 0.000 claims 1
- COFFAHPUFACRCJ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(3-methoxy-1,2-oxazol-5-yl)methanone Chemical compound O1N=C(OC)C=C1C(=O)N1CC2CNCC2C1 COFFAHPUFACRCJ-UHFFFAOYSA-N 0.000 claims 1
- XCORZZYKCQYSQJ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(3-methylfuran-2-yl)methanone Chemical compound C1=COC(C(=O)N2CC3CNCC3C2)=C1C XCORZZYKCQYSQJ-UHFFFAOYSA-N 0.000 claims 1
- VZTZBWKJSNARCS-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(4-phenylfuran-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C(OC=1)=CC=1C1=CC=CC=C1 VZTZBWKJSNARCS-UHFFFAOYSA-N 0.000 claims 1
- GGPRUUQFBUCJMT-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(5-bromofuran-2-yl)methanone Chemical compound O1C(Br)=CC=C1C(=O)N1CC2CNCC2C1 GGPRUUQFBUCJMT-UHFFFAOYSA-N 0.000 claims 1
- VGHRMGBKIWAGMS-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(5-methylfuran-2-yl)methanone Chemical compound O1C(C)=CC=C1C(=O)N1CC2CNCC2C1 VGHRMGBKIWAGMS-UHFFFAOYSA-N 0.000 claims 1
- LYSWGSBJHWGVFD-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-(5-pyridin-2-ylfuran-2-yl)methanone Chemical compound C1C2CNCC2CN1C(=O)C(O1)=CC=C1C1=CC=CC=N1 LYSWGSBJHWGVFD-UHFFFAOYSA-N 0.000 claims 1
- NUBRAZSHSYLVMW-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl-[5-(2-phenylethynyl)furan-2-yl]methanone Chemical compound C1C2CNCC2CN1C(=O)C(O1)=CC=C1C#CC1=CC=CC=C1 NUBRAZSHSYLVMW-UHFFFAOYSA-N 0.000 claims 1
- KYLIVTKHRHWCMA-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2,4-oxadiazol-3-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1N=CON=1 KYLIVTKHRHWCMA-UHFFFAOYSA-N 0.000 claims 1
- SIVRDZKAWCUUIO-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2,4-oxadiazol-5-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=NC=NO1 SIVRDZKAWCUUIO-UHFFFAOYSA-N 0.000 claims 1
- ARYFGYLXONLXAD-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2,4-thiadiazol-3-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1N=CSN=1 ARYFGYLXONLXAD-UHFFFAOYSA-N 0.000 claims 1
- IPGZNWGMLMYWSM-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2,4-thiadiazol-5-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=NC=NS1 IPGZNWGMLMYWSM-UHFFFAOYSA-N 0.000 claims 1
- KKMPKOQLJDEKSP-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2-oxazol-3-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1C=CON=1 KKMPKOQLJDEKSP-UHFFFAOYSA-N 0.000 claims 1
- WNLXIRPOLYUMCD-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2-oxazol-4-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1C=NOC=1 WNLXIRPOLYUMCD-UHFFFAOYSA-N 0.000 claims 1
- OMWRNDBURDSUMI-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2-oxazol-5-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=CC=NO1 OMWRNDBURDSUMI-UHFFFAOYSA-N 0.000 claims 1
- WPMDYFZGCGEDCU-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2-thiazol-3-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1C=CSN=1 WPMDYFZGCGEDCU-UHFFFAOYSA-N 0.000 claims 1
- KVBYGSFSJKALSO-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2-thiazol-4-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1C=NSC=1 KVBYGSFSJKALSO-UHFFFAOYSA-N 0.000 claims 1
- YMSWEHQEGSMKLH-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,2-thiazol-5-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=CC=NS1 YMSWEHQEGSMKLH-UHFFFAOYSA-N 0.000 claims 1
- TUVLYRGJOISXFH-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3,4-oxadiazol-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=NN=CO1 TUVLYRGJOISXFH-UHFFFAOYSA-N 0.000 claims 1
- ZLCXKUZWNUXLME-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3,4-thiadiazol-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=NN=CS1 ZLCXKUZWNUXLME-UHFFFAOYSA-N 0.000 claims 1
- CFTLPIKSWDCMKR-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3-oxazol-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=NC=CO1 CFTLPIKSWDCMKR-UHFFFAOYSA-N 0.000 claims 1
- HOXARZOHBLGJES-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3-oxazol-4-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=COC=N1 HOXARZOHBLGJES-UHFFFAOYSA-N 0.000 claims 1
- HVYPEWIFRMKLAK-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3-oxazol-5-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=CN=CO1 HVYPEWIFRMKLAK-UHFFFAOYSA-N 0.000 claims 1
- KOVXOGMTDAQHMH-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3-thiazol-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=NC=CS1 KOVXOGMTDAQHMH-UHFFFAOYSA-N 0.000 claims 1
- GQLVKISITIZPMN-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3-thiazol-4-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=CSC=N1 GQLVKISITIZPMN-UHFFFAOYSA-N 0.000 claims 1
- XECNAMLXYHEYCQ-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(1,3-thiazol-5-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=CN=CS1 XECNAMLXYHEYCQ-UHFFFAOYSA-N 0.000 claims 1
- PSXPQUNJMZAIKK-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(furan-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C1=CC=CO1 PSXPQUNJMZAIKK-UHFFFAOYSA-N 0.000 claims 1
- QTLQGNUJEKVYNF-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl(furan-3-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C=1C=COC=1 QTLQGNUJEKVYNF-UHFFFAOYSA-N 0.000 claims 1
- RCDYEIPQLIIGIL-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl-(3-methoxy-1,2-oxazol-5-yl)methanone Chemical compound O1N=C(OC)C=C1C(=O)N1CC(C2)CNCC2C1 RCDYEIPQLIIGIL-UHFFFAOYSA-N 0.000 claims 1
- FDNXWEUROWLDDO-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl-(3-methylfuran-2-yl)methanone Chemical compound C1=COC(C(=O)N2CC3CNCC(C3)C2)=C1C FDNXWEUROWLDDO-UHFFFAOYSA-N 0.000 claims 1
- WRBGHVBVACEZKL-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl-(4-phenylfuran-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C(OC=1)=CC=1C1=CC=CC=C1 WRBGHVBVACEZKL-UHFFFAOYSA-N 0.000 claims 1
- ORHMDEPRGDBBCN-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl-(5-methylfuran-2-yl)methanone Chemical compound O1C(C)=CC=C1C(=O)N1CC(C2)CNCC2C1 ORHMDEPRGDBBCN-UHFFFAOYSA-N 0.000 claims 1
- XIWAHVZJCPKURQ-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl-(5-pyridin-2-ylfuran-2-yl)methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C(O1)=CC=C1C1=CC=CC=N1 XIWAHVZJCPKURQ-UHFFFAOYSA-N 0.000 claims 1
- WXZYZLCFDQSXOV-UHFFFAOYSA-N 3,7-diazabicyclo[3.3.1]nonan-3-yl-[5-(2-phenylethynyl)furan-2-yl]methanone Chemical compound C1C(C2)CNCC2CN1C(=O)C(O1)=CC=C1C#CC1=CC=CC=C1 WXZYZLCFDQSXOV-UHFFFAOYSA-N 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85607906P | 2006-11-02 | 2006-11-02 | |
| US60/856,079 | 2006-11-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535465A Division JP5539723B2 (ja) | 2006-11-02 | 2007-11-01 | ニコチン性アセチルコリン受容体サブタイプ選択的なジアザビシクロアルカンのアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013056919A JP2013056919A (ja) | 2013-03-28 |
| JP2013056919A5 true JP2013056919A5 (https=) | 2013-05-30 |
| JP5739398B2 JP5739398B2 (ja) | 2015-06-24 |
Family
ID=39233054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535465A Active JP5539723B2 (ja) | 2006-11-02 | 2007-11-01 | ニコチン性アセチルコリン受容体サブタイプ選択的なジアザビシクロアルカンのアミド |
| JP2012253103A Active JP5739398B2 (ja) | 2006-11-02 | 2012-11-19 | ニコチン性アセチルコリン受容体サブタイプ選択的なジアザビシクロアルカンのアミド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535465A Active JP5539723B2 (ja) | 2006-11-02 | 2007-11-01 | ニコチン性アセチルコリン受容体サブタイプ選択的なジアザビシクロアルカンのアミド |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US8114889B2 (https=) |
| EP (2) | EP2284171B1 (https=) |
| JP (2) | JP5539723B2 (https=) |
| KR (2) | KR101415705B1 (https=) |
| CN (4) | CN102942569B (https=) |
| AR (2) | AR063451A1 (https=) |
| AT (2) | ATE509022T1 (https=) |
| AU (2) | AU2007317433B2 (https=) |
| BR (2) | BRPI0717930A2 (https=) |
| CA (1) | CA2663925C (https=) |
| CL (1) | CL2007003155A1 (https=) |
| CO (1) | CO6180435A2 (https=) |
| CY (1) | CY1112374T1 (https=) |
| DK (1) | DK2094703T3 (https=) |
| ES (2) | ES2395157T3 (https=) |
| HR (1) | HRP20110570T1 (https=) |
| IL (2) | IL197618A (https=) |
| MX (1) | MX2009004801A (https=) |
| MY (2) | MY156730A (https=) |
| NO (1) | NO20091251L (https=) |
| NZ (2) | NZ587847A (https=) |
| PE (2) | PE20081441A1 (https=) |
| PL (1) | PL2094703T3 (https=) |
| PT (1) | PT2094703E (https=) |
| RS (1) | RS51834B (https=) |
| RU (2) | RU2448969C2 (https=) |
| SA (1) | SA07280584B1 (https=) |
| SI (1) | SI2094703T1 (https=) |
| TW (3) | TWI454262B (https=) |
| UA (2) | UA98944C2 (https=) |
| UY (1) | UY30686A1 (https=) |
| WO (1) | WO2008057938A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454262B (zh) * | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| JP2011513421A (ja) * | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| WO2009113950A1 (en) * | 2008-03-10 | 2009-09-17 | Astrazeneca Ab | Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist |
| WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| WO2009147189A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| ES2383246T3 (es) | 2008-06-05 | 2012-06-19 | Glaxo Group Limited | 4-amino-indazoles |
| WO2010028033A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| WO2010028011A1 (en) * | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| RU2417082C2 (ru) * | 2009-07-14 | 2011-04-27 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения |
| PT2513085T (pt) | 2009-11-18 | 2016-11-14 | Suven Life Sciences Ltd | Compostos bicíclicos como ligantes do recetor da acetilcolina nicotínico alfa4beta2 |
| AU2010337837B2 (en) | 2009-12-29 | 2013-09-05 | Suven Life Sciences Limited | Alpha4beta2 neuronal nicotinic acetylcholine receptor ligands |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| EP3848028B9 (en) | 2014-10-20 | 2024-10-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112017026682A2 (pt) * | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| AU2016328436B2 (en) * | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| MX385698B (es) | 2016-04-07 | 2025-03-18 | Oyster Point Pharma Inc | Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
| HUT74682A (en) * | 1993-12-29 | 1997-01-28 | Pfizer | Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them |
| US5457121A (en) | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| US6815438B2 (en) * | 1999-12-14 | 2004-11-09 | Neurosearch A/S | Heteroaryl-diazabicycloalkanes |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| EP1368354A1 (en) | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| AU2002320958B2 (en) | 2001-07-06 | 2008-02-28 | Neurosearch A/S | Novel compounds, their preparation and use |
| SE0202465D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| CN1317280C (zh) * | 2003-02-27 | 2007-05-23 | 神经研究公司 | 新的二氮杂双环芳基衍生物 |
| DE602004023586D1 (de) * | 2003-02-27 | 2009-11-26 | Neurosearch As | Neue diazabicyclische arylderivate |
| US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| ATE382623T1 (de) * | 2004-06-09 | 2008-01-15 | Hoffmann La Roche | Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln |
| WO2006012470A1 (en) | 2004-07-22 | 2006-02-02 | Cumbre Pharmaceuticals Inc. | Rifamycin derivatives for treating microbial infections |
| ES2434467T3 (es) * | 2005-05-13 | 2013-12-16 | Lexicon Pharmaceuticals, Inc. | Compuestos multicíclicos y métodos para su uso |
| TWI454262B (zh) * | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
-
2007
- 2007-10-19 TW TW101139986A patent/TWI454262B/zh not_active IP Right Cessation
- 2007-10-19 TW TW099135628A patent/TWI404532B/zh not_active IP Right Cessation
- 2007-10-19 TW TW096139391A patent/TWI405763B/zh not_active IP Right Cessation
- 2007-10-30 SA SA07280584A patent/SA07280584B1/ar unknown
- 2007-10-31 PE PE2007001487A patent/PE20081441A1/es not_active Application Discontinuation
- 2007-10-31 PE PE2011000136A patent/PE20110671A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703155A patent/CL2007003155A1/es unknown
- 2007-11-01 RU RU2009120674/04A patent/RU2448969C2/ru not_active IP Right Cessation
- 2007-11-01 RU RU2009138600/04A patent/RU2517693C2/ru not_active IP Right Cessation
- 2007-11-01 RS RS20110339A patent/RS51834B/sr unknown
- 2007-11-01 UA UAA200905474A patent/UA98944C2/ru unknown
- 2007-11-01 JP JP2009535465A patent/JP5539723B2/ja active Active
- 2007-11-01 BR BRPI0717930-8A patent/BRPI0717930A2/pt not_active IP Right Cessation
- 2007-11-01 CN CN201210401679.6A patent/CN102942569B/zh not_active Expired - Fee Related
- 2007-11-01 CN CN201210291637.1A patent/CN102838605B/zh not_active Expired - Fee Related
- 2007-11-01 CN CN2010105367790A patent/CN102020646B/zh not_active Expired - Fee Related
- 2007-11-01 AR ARP070104876A patent/AR063451A1/es not_active Application Discontinuation
- 2007-11-01 MY MYPI2011004927A patent/MY156730A/en unknown
- 2007-11-01 UY UY30686A patent/UY30686A1/es not_active Application Discontinuation
- 2007-11-01 AU AU2007317433A patent/AU2007317433B2/en not_active Ceased
- 2007-11-01 ES ES10075738T patent/ES2395157T3/es active Active
- 2007-11-01 NZ NZ587847A patent/NZ587847A/en not_active IP Right Cessation
- 2007-11-01 EP EP10075738A patent/EP2284171B1/en active Active
- 2007-11-01 PL PL07863786T patent/PL2094703T3/pl unknown
- 2007-11-01 WO PCT/US2007/083330 patent/WO2008057938A1/en not_active Ceased
- 2007-11-01 CN CN2007800402281A patent/CN101528745B/zh not_active Expired - Fee Related
- 2007-11-01 KR KR1020097008122A patent/KR101415705B1/ko not_active Expired - Fee Related
- 2007-11-01 US US12/447,850 patent/US8114889B2/en not_active Expired - Fee Related
- 2007-11-01 EP EP07863786A patent/EP2094703B1/en active Active
- 2007-11-01 SI SI200730628T patent/SI2094703T1/sl unknown
- 2007-11-01 BR BRPI0722387-0A patent/BRPI0722387A2/pt not_active Application Discontinuation
- 2007-11-01 NZ NZ575557A patent/NZ575557A/en not_active IP Right Cessation
- 2007-11-01 DK DK07863786.5T patent/DK2094703T3/da active
- 2007-11-01 AT AT07863786T patent/ATE509022T1/de active
- 2007-11-01 UA UAA200912807A patent/UA106718C2/uk unknown
- 2007-11-01 HR HR20110570T patent/HRP20110570T1/hr unknown
- 2007-11-01 CA CA2663925A patent/CA2663925C/en not_active Expired - Fee Related
- 2007-11-01 MX MX2009004801A patent/MX2009004801A/es active IP Right Grant
- 2007-11-01 KR KR1020107025973A patent/KR20100124356A/ko not_active Abandoned
- 2007-11-01 AT AT10075738T patent/ATE545646T1/de active
- 2007-11-01 ES ES07863786T patent/ES2395212T3/es active Active
- 2007-11-01 MY MYPI20091569A patent/MY145602A/en unknown
- 2007-11-01 PT PT07863786T patent/PT2094703E/pt unknown
-
2009
- 2009-03-16 IL IL197618A patent/IL197618A/en not_active IP Right Cessation
- 2009-03-26 NO NO20091251A patent/NO20091251L/no not_active Application Discontinuation
- 2009-06-01 CO CO09056352A patent/CO6180435A2/es active IP Right Grant
-
2010
- 2010-03-15 US US12/723,790 patent/US8268860B2/en not_active Expired - Fee Related
- 2010-09-07 AU AU2010219323A patent/AU2010219323B2/en not_active Ceased
- 2010-10-31 IL IL209026A patent/IL209026A/en not_active IP Right Cessation
-
2011
- 2011-01-05 AR ARP110100026A patent/AR079840A2/es not_active Application Discontinuation
- 2011-07-20 CY CY20111100706T patent/CY1112374T1/el unknown
-
2012
- 2012-01-03 US US13/342,635 patent/US8859609B2/en active Active
- 2012-07-23 US US13/555,458 patent/US8921410B2/en active Active
- 2012-11-19 JP JP2012253103A patent/JP5739398B2/ja active Active
-
2014
- 2014-11-24 US US14/551,498 patent/US20150080576A1/en not_active Abandoned
-
2015
- 2015-10-26 US US14/922,473 patent/US9580434B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013056919A5 (https=) | ||
| JP2014506907A5 (https=) | ||
| JP2018531941A5 (https=) | ||
| JP2016516043A5 (https=) | ||
| JP2014507455A5 (https=) | ||
| JP2014511892A5 (https=) | ||
| JP2016513696A5 (https=) | ||
| JP2015537020A5 (https=) | ||
| JP2011529054A5 (https=) | ||
| JP2013032389A5 (https=) | ||
| JP2013545785A5 (https=) | ||
| JP2016503052A5 (https=) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2013537203A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2015504081A5 (https=) | ||
| EP4582424A3 (en) | 1,2-naphthoquinone derivative and method for preparing same | |
| WO2012099942A3 (en) | Methods and compositions for treating metabolic syndrome | |
| JP2015516427A5 (https=) | ||
| JP2015536947A5 (https=) | ||
| JP2015535847A5 (https=) | ||
| JP2016504400A5 (https=) | ||
| JP2017538753A5 (https=) | ||
| JP2013542267A5 (https=) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 |